Antidepressant-like and anxiolytic-like effects of hydrogen sulfide in behavioral models of depression and anxiety

Behavioural Pharmacology

Volumn 24, Issue 7, 2013, Pages 590-597

  Chen, Wen Lin ^a   Xie, Bin ^a   Zhang, Chong ^a   Xu, Kang Li ^a   Niu, Ying Ying ^a   Tang, Xiao Qing ^a   Zhang, Ping ^a   Zou, Wei ^a   Hu, Bi ^a   Tian, Ying ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Anxiety; Depression; Elevated plus maze; Forced swimming test; Hydrogen sulfide; Mouse, rat; Tail suspension test

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYDROGEN SULFIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG SCREENING; ELEVATED PLUS MAZE TEST; EXPERIMENTAL TEST; FORCED SWIMMING TEST; MALE; MAZE TEST; MOUSE; NONHUMAN; RAT; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HIPPOCAMPUS; IMMOBILIZATION; LONG TERM POTENTIATION; SWIMMING; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB SUSPENSION; HIPPOCAMPUS; HYDROGEN SULFIDE; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MICE; RATS; RATS, WISTAR; SWIMMING;

EID: 84888306350     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283654258     Document Type: Article

References (58)

1. Abe K, Kimura H (1996). The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16:1066-1071.
2. Cassano P, Fava M (2004). Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 16:15-25.
3. Chang L, Geng B, Yu F, Zhao J, Jiang H, Du J, et al. (2008). Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids 34:573-585.
4. Denollet J, Maas K, Knottnerus A, Keyzer JJ, Pop VJ (2009). Anxiety predicted premature all-cause and cardiovascular death in a 10-year follow-up of middle-aged women. J Clin Epidemiol 62:452-456.
5. Detke MJ, Rickels M, Lucki I (1995). Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121:66-72.
6. Dulawa SC, Holick KA, Gundersen B, Hen R (2004). Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29:1321-1330.
7. Eto K, Ogasawara M, Umemura K, Nagai Y, Kimura H (2002). Hydrogen sulfide is produced in response to neuronal excitation. J Neurosci 22:3386-3391.
8. Garcia-Bereguiain MA, Samhan-Arias AK, Martin-Romero FJ, Gutierrez-Merino C (2008). Hydrogen sulfide raises cytosolic calcium in neurons through activation of L-type Ca2+ channels. Antioxid Redox Signal 10:31-42.
9. Gomes PB, Feitosa ML, Silva MI, Noronha EC, Moura BA, Venancio ET, et al. (2010). Anxiolytic-like effect of the monoterpene 1,4-cineole in mice. Pharmacol Biochem Behav 96:287-293.
10. Gorman JM (2003). Treating generalized anxiety disorder. J Clin Psychiatry 64 (Suppl 2):24-29.
11. Gorwood P (2004). Generalized anxiety disorder and major depressive disorder comorbidity: An example of genetic pleiotropy Eur Psychiatry 19:27-33.
12. Hajikhani R, Ahmadi A, Naderi N, Yaghoobi K, Shirazizand Z, Rezaee NM, et al. (2012). Effect of phencyclidine derivatives on anxiety-like behavior using an elevated-plus maze test in mice. Adv Clin Exp Med 21:307-312.
13. Haller J, Alicki M (2012). Current animal models of anxiety, anxiety disorders, and anxiolytic drugs. Curr Opin Psychiatry 25:59-64.
14. Han Y, Qin J, Chang X, Yang Z, Bu D, Du J (2005a). Modulating effect of hydrogen sulfide on gamma-aminobutyric acid B receptor in recurrent febrile seizures in rats. Neurosci Res 53:216-219.
15. Han Y, Qin J, Chang X, Yang Z, Tang X, Du J (2005b). Hydrogen sulfide may improve the hippocampal damage induced by recurrent febrile seizures in rats. Biochem Biophys Res Commun 327:431-436.
16. Hogg S (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54:21-30.
17. Hu LF, Lu M, Wu ZY, Wong PT, Bian JS (2009). Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function. Mol Pharmacol 75:27-34.
18. Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, et al. (2004). Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 34:597-611.
19. Kastenschmidt EK, Kennedy GJ (2011). Depression and anxiety in late life: diagnostic insights and therapeutic options. Mt Sinai J Med 78:527-545.
20. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105.
21. Kida K, Yamada M, Tokuda K, Marutani E, Kakinohana M, Kaneki M, et al. (2011). Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinsons disease. Antioxid Redox Signal 15:343-352.
22. Kim CS, Chang PY, Johnston D (2012). Enhancement of dorsal hippocampal activity by knockdown of HCN1 channels leads to anxiolytic-and antidepressant-like behaviors. Neuron 75:503-516.
23. Kimura H (2000). Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. Biochem Biophys Res Commun 267:129-133.
24. Kimura H (2002). Hydrogen sulfide as a neuromodulator. Mol Neurobiol 26:13-19.
25. Kimura Y, Kimura H (2004). Hydrogen sulfide protects neurons from oxidative stress. FASEB J 18:1165-1167.
26. Lamers F, Van Oppen P, Comijs HC, Smit JH, Spinhoven P, Van Balkom AJ, et al. (2011). Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 72:341-348.
27. Lee B, Sur B, Yeom M, Shim I, Lee H, Hahm DH (2012). Effect of berberine on depression-and anxiety-like behaviors and activation of the noradrenergic system induced by development of morphine dependence in rats. Korean J Physiol Pharmacol 16:379-386.
28. Lee SW, Hu YS, Hu LF, Lu Q, Dawe GS, Moore PK, et al. (2006). Hydrogen sulphide regulates calcium homeostasis in microglial cells. Glia 54:116-124.
29. Lepine JP, Briley M (2011). The increasing burden of depression. Neuropsychiatr Dis Treat 7:3-7.
30. Lowicka E, Beltowski J (2007). Hydrogen sulfide (H2S)-the third gas of interest for pharmacologists. Pharmacol Rep 59:4-24.
31. Lu M, Choo CH, Hu LF, Tan BH, Hu G, Bian JS (2010). Hydrogen sulfide regulates intracellular pH in rat primary cultured glia cells. Neurosci Res 66:92-98.
32. Moore PK, Bhatia M, Moochhala S (2003). Hydrogen sulfide: from the smell of the past to the mediator of the future Trends Pharmacol Sci 24:609-611.
33. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147:162-167.
34. Pinheiro SH, Zangrossi H Jr, Del-Ben CM, Graeff FG (2007). Elevated mazes as animal models of anxiety: effects of serotonergic agents. An Acad Bras Cienc 79:71-85.
35. Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391.
36. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, et al. (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2:590-611.
37. Schreier SM, Muellner MK, Steinkellner H, Hermann M, Esterbauer H, Exner M, et al. (2010). Hydrogen sulfide scavenges the cytotoxic lipid oxidation product 4-HNE. Neurotox Res 17:249-256.
38. Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, et al. (2012). Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 235:302-317.
39. Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, et al. (2002). Fluoxetine treatment of depressed patients with comorbid anxiety disorders. J Psychopharmacol 16:215-219.
40. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367-370.
41. Szabo C (2007). Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917-935.
42. Takahashi M, Kaneto H (1995). Assessment of anxiolytics (6)-a novel method in mice using psychological stress. Nihon Shinkei Seishin Yakurigaku Zasshi 15:375-383.
43. Tan BH,Wong PT, Bian JS (2010). Hydrogen sulfide: A novel signaling molecule in the central nervous system. Neurochem Int 56:3-10.
44. Tang XQ, Yang CT, Chen J, Yin WL, Tian SW, Hu B, et al. (2008). Effect of hydrogen sulphide on beta-amyloid-induced damage in PC12 cells. Clin Exp Pharmacol Physiol 35:180-186.
45. Tiong CX, Lu M, Bian JS (2010). Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway. Br J Pharmacol 161:467-480.
46. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. (2009). Adverse reactions to antidepressants. Br J Pharmacol 195:202-210.
47. Verhoof E, Maurice-Stam H, Heymans H, Grootenhuis M (2013). Health-related quality of life, anxiety and depression in young adults with disability benefits due to childhood-onset somatic conditions. Child Adolesc Psychiatry Ment Health 7:12.
48. Wang R (2002). Twos company, threes a crowd: can H2S be the third endogenous gaseous transmitter FASEB J 16:1792-1798.
49. Wang R (2010). Hydrogen sulfide: the third gasotransmitter in biology and medicine. Antioxid Redox Signal 12:1061-1064.
50. Wang R (2012). Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol Rev 92:791-896.
51. Wong ML, Licinio J (2001). Research and treatment approaches to depression. Nat Rev Neurosci 2:343-351.
52. Yang G,Wu L, Jiang B, Yang W, Qi J, Cao K, et al. (2008). H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gammalyase. Science 322:587-590.
53. Yang W, Yang G, Jia X, Wu L, Wang R (2005). Activation of KATP channels by H2S in rat insulin-secreting cells and the underlying mechanisms. J Physiol 569:519-531.
54. Yin WL, He JQ, Hu B, Jiang ZS, Tang XQ (2009). Hydrogen sulfide inhibits MPP(+)-induced apoptosis in PC12 cells. Life Sci 85:269-275.
55. Yong QC, Choo CH, Tan BH, Low CM, Bian JS (2010). Effect of hydrogen sulfide on intracellular calcium homeostasis in neuronal cells. Neurochem Int 56:508-515.
56. Zhao W, Zhang J, Lu Y, Wang R (2001). The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 20:6008-6016.
57. Zhao W, Wang R (2002). H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol 283:H474-H480.
58. Zhou CF, Tang XQ (2011). Hydrogen sulfide and nervous system regulation. Chin Med J 124:3576-3582.